Five profiles tracing the molecule from academic peptide design to receptor pharmacology to the clinic — and the definitive roster of everyone who built it.
Tirzepatide was not invented by a single person, but rather by a collaborative team of medicinal chemists and biologists at Eli Lilly and Company, who built upon foundational academic research.
If we break down "who invented it" based on their specific contributions, the credit belongs to the following key figures:
1. The Internal Champion & Lead Discoverer: Dr. Tamer Coskun
As a lead researcher (and now Vice President-Medical) at Eli Lilly, Dr. Coskun is widely considered the primary internal architect of tirzepatide. He was the lead author of the foundational 2018 paper that introduced the molecule (then known as LY3298176) to the world, and he held the unique dual role of overseeing both its discovery and its early-phase human clinical trials.
2. The Chemical Inventors: Krister B. Bokvist & Eli Lilly's Chemistry Team
The actual physical molecule—the specific sequence of amino acids, the protective substitutions to prevent enzyme degradation, and the fatty-acid side chain that allows for once-weekly dosing—was synthesized by Lilly’s medicinal chemists. Krister B. Bokvist is listed as a primary named inventor on the core patents detailing the chemical synthesis and structure of tirzepatide.
3. The Conceptual Pioneers: Dr. Richard DiMarchi, Dr. Brian Finan, & Dr. Matthias Tschöp
The underlying concept of tirzepatide was born in academia. The idea that a single, engineered "unimolecular" peptide could simultaneously activate both the GIP and GLP-1 receptors (a dual agonist) was proven in a landmark 2013 paper. Dr. Richard DiMarchi (a pioneering peptide chemist at Indiana University), along with Dr. Brian Finan and Dr. Matthias Tschöp, provided the exact biological blueprint that proved this dual-action approach was vastly superior to single-hormone drugs like Ozempic. Eli Lilly used this blueprint to develop tirzepatide.
4. The Pharmacologists & Biologists: Dr. Kyle W. Sloop, Dr. Daniel A. Briere, & Dr. Francis S. Willard
These Eli Lilly scientists were crucial co-authors on the foundational papers. They conducted the rigorous preclinical testing that revealed tirzepatide’s unique "imbalanced and biased" signaling profile (meaning it favors the GIP receptor over the GLP-1 receptor in a specific way), which ultimately explained why the drug causes such profound weight loss with fewer gastrointestinal side effects than older drugs.
In summary:
Eli Lilly and Company owns the invention. Krister Bokvist's team built the physical molecule, Tamer Coskun led its biological validation and translation to human patients, and Richard DiMarchi/Brian Finan invented the underlying scientific concept that made the dual-agonist class possible.
From peptide chemists and receptor pharmacologists to patent chemists and clinical trial leads — the definitive account of everyone whose work converged on Mounjaro and Zepbound, from Richard DiMarchi's co-agonist chemistry to Ania Jastreboff's SURMOUNT-1 trial.
Read the rosterThe architect of the twincretin molecule itself. From Bruce Merrifield's lab to two decades re-engineering insulin at Eli Lilly, DiMarchi's academic return produced the unimolecular co-agonist design at the structural heart of tirzepatide.
Read the profileThe translational bridge between Bloomington chemistry and Munich physiology. Finan's 2013 unimolecular dual-incretin paper proved the co-agonist concept in rodents, primates, and humans — then extended the same logic to triple and quintuple agonists.
Read the profileThe translator who moved tirzepatide from hypothesis to human. Lead author of the 2018 paper that introduced LY3298176 to the world, Coskun's hybrid discovery-and-clinical mandate collapsed the wall between bench and bedside.
Read the profileThe scientist who explained why tirzepatide works. From an evening PhD at IUPUI to corresponding authorship with a Nobel laureate's lab, Sloop decoded tirzepatide's "imbalanced, biased" mechanism — then helped move GLP-1 medicine from the needle to the pill.
Read the profile